Logo Logo
Switch Language to German
Weber-Lassalle, Konstantin; Harter, Philipp; Hauke, Jan; Ernst, Corinna; Kommoss, Stefan; Marme, Frederik; Weber-Lassalle, Nana; Prieske, Katharina; Dietrich, Dimo; Borde, Julika; Pohl-Rescigno, Esther; Reuss, Alexander; Ataseven, Beyhan; Engel, Christoph; Stingl, Julia C.; Schmutzler, Rita K.; Hahnen, Eric (2018): Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis Results of the observational AGO-TR1 trial. In: Human Mutation, Vol. 39, No. 12: pp. 2040-2046
Full text not available from 'Open Access LMU'.


The Li-Fraumeni cancer predisposition syndrome (LFS1) presents with a variety of tumor types and the TP53 gene is covered by most diagnostic cancer gene panels. We demonstrate that deleterious TP53 variants identified in blood-derived DNA of 523 patients with ovarian cancer (AGO-TR1 trial) were not causal for the patients' ovarian cancer in three out of six TP53-positive cases. In three out of six patients, deleterious TP53 mutations were identified with low variant fractions in blood-derived DNA but not in the tumor of the patient seeking advice. The analysis of the TP53 and PPM1D genes, both intimately involved in chemotherapy-induced and/or age-related clonal hematopoiesis (CH), in 523 patients and 1,053 age-matched female control individuals revealed that CH represents a frequent event following chemotherapy, affecting 26 of the 523 patients enrolled (5.0%). Considering that TP53 mutations may arise from chemotherapy-induced CH, our findings help to avoid false-positive genetic diagnoses of LFS1.